Vidac Pharma sees growing recognition of its innovative approach to fight cancer

London (UK), January 22, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company  pioneering a groundbreaking new way of treating cancer, at an international investor conference late last year welcomed  growing recognition by academics and the pharmaceutical community of the science behind its oncologic and onco-dermatologic drug candidates to treat diseases such as Actinic Keratosis (AK), Cutaneous T-Cell Lymphoma (CTCL) and a wide range of solid tumors.

“It is not always necessary to use toxic agents to fight cancer, because the collateral damaged caused, for example, by conventional chemotherapy is very high. [This idea represents] a new concept, a new paradigm in the search for new drugs, and particularly against cancer,” said Prof. Max Herzberg, CEO of Vidac Pharma, speaking at the HealthTech Innovation Days conference, where he moderated an expert panel on non-violent therapies in front of international investors, representatives of pharma companies and patient organisations.

Vidac Pharma is developing a breakthrough new technology which reverses the abnormal metabolism of cancer cells – known as the Warburg effect - by preventing the Hexokinase 2 (HK2) enzyme from blocking the VDAC mitochondrial relay channels. Clinical data have shown the powerful effects this can have in halting cancer cell proliferation and tumor immune-resistance, as well restoring programmed cell death. Vidac’s lead drug, VDA-1102 is at the clinical development stage for patients with actinic keratosis, an early form of skin cancer, and in a separate trial for an indication of cutaneous T-cell lymphoma (CTCL).

For more information please contact: 

About Vidac Pharma

Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma was proven effective against advanced Actinic Keratosis (AK) and Cutaneous T-cell Lymphoma (CTCL) in Phase 2 trials in humans.
www.vidacpharma.com

Important information

The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.